|
| U.S. Brand
Names |
|
| Diapid® Nasal
Spray |

|
|
| Generic
Available |
|
|
No |

|
|
| Synonyms |
|
|
8- L-Lysine Vasopressin |

|
|
| Pharmacological Index |
|
|
Antidiuretic Hormone Analog |

|
|
| Use |
|
|
Controls or prevents signs and complications of neurogenic diabetes
insipidus |

|
|
| Pregnancy Risk
Factor |
|
|
C |

|
|
| Contraindications |
|
|
Known hypersensitivity to lypressin |

|
|
| Warnings/Precautions |
|
|
Use with caution in patients with coronary artery
disease |

|
|
| Adverse
Reactions |
|
|
1% to 10%:
Cardiovascular: Chest tightness
Central nervous system: Dizziness, headache
Endocrine & metabolic: Water intoxication
Gastrointestinal: Abdominal cramping, increased bowel movements
Local: Irritation or burning
Respiratory: Coughing, dyspnea, rhinorrhea, nasal congestion
<1%: Inadvertent inhalation |

|
|
| Overdosage/Toxicology |
|
|
Symptoms of overdose include drowsiness, headache, confusion, weight gain,
hypertension; systemic toxicity is unlikely to occur from the nasal
spray |

|
|
| Drug
Interactions |
|
|
Increased effect: Chlorpropamide, clofibrate, carbamazepine
prolongation of
antidiuretic
effects |

|
|
| Mechanism of
Action |
|
|
Increases cyclic adenosine monophosphate (cAMP) which increases water
permeability at the renal tubule resulting in decreased urine volume and
increased osmolality; causes peristalsis by directly stimulating the smooth
muscle in the GI tract |

|
|
| Pharmacodynamics/Kinetics |
|
|
Onset of antidiuretic effect: Intranasal spray: Within 0.5-2 hours
Duration: 3-8 hours
Metabolism: In the liver and kidneys
Half-life: 15-20 minutes
Elimination: Urinary excretion |

|
|
| Usual Dosage |
|
|
Children and Adults: Instill 1-2 sprays into one or both nostrils whenever
frequency of urination increases or significant thirst develops; usual dosage is
1-2 sprays 4 times/day; range: 1 spray/day at bedtime to 10 sprays each nostril
every 3-4 hours |

|
|
| Mental Health: Effects
on Mental Status |
|
|
May cause dizziness |

|
|
| Mental Health:
Effects on Psychiatric
Treatment |
|
|
Carbamazepine may produce prolongation of antidiuretic
effects |

|
|
| Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
|
No information available to require special precautions |

|
|
| Dental Health:
Effects on Dental Treatment |
|
|
No effects or complications reported |

|
|
| Patient
Information |
|
|
To control nocturia, an additional dose may be given at bedtime. Notify
prescriber if drowsiness, fatigue, headache, shortness of breath, abdominal
cramps, or severe nasal irritation occurs. Pregnancy precautions: Inform
prescriber if you are or intend to be pregnant. |

|
|
| Nursing
Implications |
|
|
Approximately 2 USP posterior pituitary pressor units per
spray |

|
|
| Dosage Forms |
|
|
Spray: 0.185 mg/mL (equivalent to 50 USP posterior pituitary units/mL) (8
mL) |

|
|
Copyright © 2007 Drugs Area
|